ADC Drug Map

CLICK ON THE HUMAN TO SEE WHICH ADCs ARE BEING DEVELOPED FOR THAT SPECIFIC ORGAN

Filter by Cancer

• Bladder cancer
• Myeloma
• Leukemia
• Breast cancer
• Colon cancer
• Esophageal cancer
• Kidney cancer
• Colorectal cancer
• Liver cancer
• Lung cancer
• Hodgkin's disease
• Lymphoma
• Mesenteric Lymphadenitis
• Ovarian cancer
• Pancreatic cancer
• Prostate cancer
• Rectal cancer
• Skin cancer
• Small Intestine cancer
• Spleen cancer
• Stomach cancer
• Uterine cancer
• White blood cells

ADC

Clear Filter

• AB-3A4 ADCAlethia Biotherapeutics
• ABBV-176 (ABV176)Abbvie
• AbGn-107 (Ab1-18Hr1)AbGenomics BV | Taiwan Branch
• AbGn-108AbGenomics International
• AbGn-110AbGenomics International
• ADCT-502ADC Terapeutics
• ADCT-601ADC Therapeutics
• ADCT-602 (hLL2-cys-PBD)ADC Therapeutics
• ADCT-701ADC Therapeutics
• AGS-16C3F (AGS 16C3F / AGS-16M8F)Agensys/Astellas
• AGS-16M8F (AGS 16C3F / AGS-16C3F)Agensys/Astellas
• AGS-22M6EAstellas Pharma Inc/Agensys, Inc. Seattle Genetics, Inc.
• AGS62P1Agensys/Astellas
• ALT-P73SBIO | Alteogen
• AMG 224Amgen
• AMG-595Amgen
• AMG172Amgen, Inc
• Anetumab Ravtansine (BAY 94-9343)Bayer HealthCare Pharmaceuticals in association with ImmunoGen Inc.
• Anti-ADAM9 ADC (Anti-ADAM9-sulfoSPDB-DM4)Macrogenics and ImmunoGen
• Anti-ADAM9 ADC (Anti-ADAM9(C442)-DGN549)Macrogenics and ImmunoGen
• Anti-CD19 ATAC (anti-CD19 ADC)Heidelberg Pharma/Wilex
• Anti-CD22-NMS249Genentech and Nerviano Medical Sciences
• Anti-CD70-ADC (CD70-ADC)Ambrx
• Anti-cMET ADC (CBT-161)Sorrento Therapeutics
• Anti-endosialin-MC-VC-PABC-MMAEGenzyme
• Anti-ETBR (RG-7636)Genentech/Roche
• anti-HER-3 ADCMediaPharma
• anti-TEM-1 Antibody-Drug Conjugate (TEM-1-ADC).MediaPharma S.r.l.
• Anti-TM4SF1 ADCThe Center for Vascular Biology Research and the Departments of Angiex; Pfizer; Pathology, Beth Israel Deaconess Medical Center (BIDMC); Harvard Medical School, Boston, Massachusetts
• Aprutumab ixadotin (BAY 1187982)Bayer HealthCare Pharmaceuticals
• AR-001 | YBL-001Y-Biologics
• ARX517-PSMA-ADCAmbrx
• ARX788 HER2 ADCZhejiang Medicine Co. | Ambrx
• ASG-22CEAstellas Pharma Inc/Agensys, Inc. Seattle Genetics, Inc.
• ASG-5MEAgensys/Astellas
• ASN-004 (ASN 004)Asana Biosciences
• AVID100Formation Biologics
• AVID300 | AVID 300Formation Biologics
• Azintuxizumab vedotin (ABBV-838)AbbVie
• Azonafide-ADCOncolinx
• BA3011 | CAB-Axl-ADC (CAB-anti-Axl-ADC)BioAtla
• BA3021 | Anti-ROR2 ADCBioAtla
• BAY79-4620Bayer HealthCare
• Belantamab mafodotin
• BIIB-015 | BIIB015Biogen
• Bivatuzumab mertansineBoehringer Ingelheim (ImmunoGen)
• Brentuximab vedotin (SGN35 / Adcetris®)Seattle genetics, Inc. (Bothell WA USA) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan)
• Bstrongximab-ADCCureMeta
• BT1718 (BT 1718)Bicycle Therapeutics
• c-MET ADCConcortis Biotherapeutics
• Camidanlumab tesirine (ADCT-301 | HuMax-TAC-ADC)Genmab | ADC Therapeutics
• Cantuzumab mertansine (huC242-DM1)GlaxoSmithKline / ImmunoGen
• Cantuzumab Ravtansine (IMGN-242)ImmunoGen
• CD184-Dasatinib (CD184-Dasatinib-ADC)Ambrx
• CD184-FK506Ambrx
• CD22-4APCatalent Pharma Solutions and Triphase Accelerator Corporation
• CD70-glucocorticoid ADCMerck & Co and Ambrx
• CDX-014Celldex Therapeutics
• Clivatuzumab TetraxetanImmunmedics
• CMB-401 | hCTMO1-calicheamicin | CDP-671Pfizer (Wyeth Pharmaceuticals); Celltech
• Cofetuzumab pelidotin (PF-06647020)Pfizer / Stemcentrx (AbbVie)
• Coltuximab Ravtansine (SAR 3419)ImmunoGen (previously also Sanofi)
• CX-2009Cytomx
• Cymac-001 (anti-CD163-dexamethasone ADC)Affinicon
• D3-GPC2-PBD (anti-GPC2 ADC)Children's Hospital of Philadelphia (CHOP
• DEDN6526A (RG-7636 / RG7636)Genentech/Roche
• Denintuzumab mafodotin (SGN-CD19A / SGN-19A)Seattle Genetics
• Depatuxizumab Mafodotin (ABT-414)AbbVie (prior sponsor, Abbott)
• DMOT4039A (DMOT-4039A / RG7600 / RG 7600)Genentech Inc. (South San Francisco, CA, USA) / Roche, F. Hoffmann-La Roche Ltd. (Basel, Switzerland)
• DS-1062 (TROP2 ADC)Daiichi Sankyo
• DS-7300 (B7-H3 ADC)Daiichi Sankyo Company
• DSTA4637S (Anti-S. aureus TAC; RG7861)Genentech
• EC1169Endocyte
• EC2629Endocyte
• EDC1 (DYS-ADC)Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)
• EDC9 (EDC-CD20)Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)
• EDO-772P/B776Mundipharma EDO GmbH
• EDO-B278Mundipharma EDO GmbH
• Enapotamab vedotin | HuMax-AXL-ADC | AXL-107-MMAEGenmab
• Enfortumab Vedotin (ASG-22ME / ASG-22MSE)Agensys (Santa Monica CA USA) / Seattle Genetics (Bothell WA USA) and Astellas Pharma (Tokyo, Japan).
• EP-400Esperance Pharmaceuticals
• Epratuzumab–SN-38Immunomedics
• EV20/MMAFMediapharma
• Gemtuzumab ozogamicin (Mylotarg®)Pfizer (Wyeth)
• Glembatumumab vedotin (CDX-011)Celldex Therapeutics, Inc.
• GM103GamaMabs
• GSK2857916 (J6M0-mcMMAF)GSK
• HDP-101 (Anti-CD269-ADC; Anti-CD269-amanitin-ADC)Heidelberg Pharma
• Hertuzumab VedotinRongchang Pharmaceuticals / MabPlex (Yantai, China).
• HKT288 (CDH6-ADC)Novartis and ImmunoGen
• HTI-1511Halozyme
• HuMAB-5B1-ATACWilex/Heidelberg Pharma in collaboration with MabVax
• IGN523Igenica Biotherapeutics
• IGN786Igenica Biotherapeutics
• Iladatuzumab vedotin (DCDS0780A; RO7032005)F. Hoffmann-La Roche
• IMAB027-vcMMAEGanymed Pharmaceuticals | Astellas
• IMAB362-vcMMAEAstellas (Ganymed Pharmaceuticals)
• IMB-201ImmunoBiochem
• IMB-202ImmunoBiochem
• IMGN 289ImmungoGen
• IMGN 779 | IMGN779ImmunoGen, Inc.
• IMGN-242ImmunoGen
• IMGN-388ImmunoGen
• IMGN-633 (AVE9633)ImmunoGen
• IMMU-140 (anti-HLA-DR-SN-38 ADC)Immunomedics
• Indatuximab Ravtansine (BT-062)ImmunoGen | BioTest
• Industuzumab Vedotin (MLN-0264 | TAK-264)Takeda / Millennium Pharmaceuticals
• Inotuzumab ozogamicin (CMC-544) | BESPONSA®Pfizer (Wyeth Pharmaceuticals)
• KTN0125Kolltan Pharmaceuticals
• KTN0182AKolltan Pharmaceuticals
• Labetuzumab govitecan (IMMU-130)Immunomedics
• Ladiratuzumab vedotin (SGN-LIV1A; Anti-LIV-1 ADC)Seattle Genetics
• Laprituximab emtansine (IMGN-289, IMGN289)ImmunoGen
• LCB14-0110 (Herceptin-LC-LBG-MMAF)Legochem Biosciences and Fosun Pharma
• LCB14-15nmLegoChem Biosciences and Takeda
• LCB14-15xxLegoChem Biosciences and Y-Biologics
• LCB14-15xx (NNV019)LegoChem Biosciences and Nordic Nanovector
• LCB14-17nnLegoChem Biosciences and Gree Cross
• LCB14-19nmLegoChem Biosiences and Samsung Medical Center
• LCB14-2nmLegoChem Biosciences and Seasun Biomaterials
• Lifastuzumab Vedotin (RG-7599 / DNIB0600A)Roche, F. Hoffmann-La Roche / Genentech
• Loncastuximab tesirine (ADCT-402)ADC Therapeutics SARL
• LOP628 (LOP-628)Novartis Pharmaceuticals
• Lorvotuzumab mertansine (IMGN-901)ImmunoGen
• Losatuxizumab vedotin (ABBV-221)AbbVie
• Lupartumab amadotin (BAY 1129980)Bayer
• LY3076226Eli Lilly and Company
• MDX-060 / iratumumabMedarex/Bristol-Myers Squibb
• MDX-1203 | BMS936561Medarex | Bristol-Myers Squibb
• MEDI-547MedImmune
• MEDI3726 | ADCT-401ADC Therapeutics in collaboration with MedImmune/AstraZeneca
• MEDI4276 (MEDI 4276)Medimmune / AstraZeneca
• MEN1309 | OBT076Co-developed by Menarini Ricerche and Oxford BioTherapeutics
• MGC018; Anti-B7-H3 ADCMacroGenics
• MI130004PharmaMar
• Milatuzumab doxorubicin (hLL1-DOX | IMMU-110)Immunomedics
• Mirvetuximab Soravtansine (IMGN-853)ImmunoGen (Cambridge MA USA)
• MLN-2704 | MLN2704Millennium/ Takeda
• MM-302Merrimack Pharmaceuticals, Inc.
• MORAb-202Morphotek®, a subsidiary of Eisai
• Naratuximab emtansine (IMGN529 | K7153A) | Debio 1562 )ImmunoGen | Debiopharm Internaltional
• NC-6201 (ADCM-E7974)NanoCarrier Co.,Ltd (Japan) and Eisai
• NV101 (Doxorubicin-anti-CD99)NanoValent Pharmaceuticals
• NV102 (Doxorubicin-anti-CD19)NanoValent Pharmaceuticals
• NV103 (Irinotecan-anti-CD99)NanoValent Pharmaceuticals
• OBI-999 | Anti-Globo H ADCOBI Pharma
• OMTX503 (Anti-MTX3:Nigrin Immunoconjugate)Oncomatryx Biopharma
• OMTX705 (Anti-MTX5:Cytolysin ADC)Oncomatryx Biopharma
• OXS-1550 (DT2219ARL)GT Biopharma. Previously known as Oxis Biotech (Georgetown Translational Pharmaceuticals)
• PCA062 (PCA-062)ImmunogGen and Novartis
• PEN-221Tarveda Therapeutics
• PF 06263507 (A1-mcMMAF | Anti-5T4 monoclonal antibody | PF-06263507 | PF06263507)Oxford BioMedica; Pfizer (Wyeth)
• PF-06647263 (anti-EFNA4-ADC)Pfizer
• PF-06650808 (Anti-NOTCH3 ADC)Pfizer (Wyeth)
• PF-06664178 | PF06664178 | PF 06664178Pfizer (Wyeth)
• PF-06688992 | PF06688992Memorial Sloan-Kettering Cancer Center; Pfizer
• PF-06804103 (Anti-NG-HER2 ADC)Pfizer
• Pinatuzumab vedotin (RG-7593 / DCDT2980S / DCDT-2989S)Genentech / Roche, F. Hoffmann-La Roche (Roche)
• Polatuzumab vedotin (RG-7596 / DCDS4501A / DCDS-4501A)Genentech / Roche, F. Hoffmann-La Roche
• PSMA-ADCProgenics Pharmaceuticals, Inc. (Tarrytown NY USA)
• Q5-Drug ConjugateAlteogen
• RC-48 (RC 48-ADC)Yantai Rongchang Biological Engineering (RemeGen)
• REGN2878-DM1 (Anti-PRLR-ADC)Regeneron
• RG-7598 (DFRF 4539A / RG7598 / RG 7598)Genentech/Roche
• RG-7841 (Anti-Ly6E / DLYE5953A)Genentech/Roche (in collaboration with Seattle Genetic)
• RG7986Genentech/Roche
• RM-1929Aspyrian Therapeutics, Inc.
• Rovalpituzumab tesirine (Rova-T | SC0001)Stemcentrx (now part of AbbVie)
• Sacituzumab govitecan (IMMU-132 / hRS7-SN38)Immunomedics
• Samrotamab vedotinAbbVie
• SAR 566658 (SAR566658)Sanofi; ImmunoGen
• SAR408701 | SAR 408701Sanofi | ImmunoGen
• SAR428926ImmunoGen; Sanofi
• Satoreotide tetraxetan
• SC-006AbbVie | Stemcentrx
• SC16LD6.5Stem CentRx
• SGN CD70 A | SGN-CD70A (superseding SGN-75)Seattle Genetics
• SGN-15 (BMS-182248, BR96-DOX)Seattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)
• SGN-CD123A
• SGN-CD19BSeattle Genetics
• SGN-CD352aSeattle Genetics
• Sirtratumab vedotin (ASG-15ME)Co-developed by Agensys/Astellas and Seattle Genetics
• SNG-8023 ADCShenogen Pharma Group
• Sofituzumab vedotin (Anti-MUC16 ADC / RG7458 / DMUC5754A)Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
• ST1Siamab Therapeutics
• STRO-001 (Anti-CD74-ADC)Sutro Biopharma
• SΤRO-002Sutro Biopharma
• Tacatuzumab Tetraxetan
• Telisotuzumab Vedotin (ABBV 399; ABBV399)AbbVie
• TGM-001Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
• TGM-002Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
• TGM-003Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
• TGM-004Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
• TGM-005Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
• Tisotumab Vedotin (HuMax®-TF-ADC)Co-developed by Genmab and Seattle Genetics
• Trastuzumab deruxtecan (DS-8201, DS-8201a)Daiichi Sankyo Inc.
• Trastuzumab duocarmazine (SYD985)Synthon Biopharmaceuticals
• Trastuzumab-emtansine (T-DM1)Genentech/Roche
• TRPH-222 (CD22-4AP)Triphase Accelerator Corporation, in collaboration with Celgene
• U3-1402 (HER3 ADC)Daiichi Sankyo
• Vadastuximab talirine (SGN-CD33A)Seattle Genetics
• Vandortuzumab vedotin (RG7450; DSTP3086S)Genentech/ F. Hoffmann-La Roche (Roche)
• Vorsetuzumab mafodotin (SGN-75)Seattle genetics
• VYNFINIT® | Vintafolide (EC145/MK 8109)Endocyte, Merck/MSD
• XMT-1522Mersana Therapeutics in collaboration with Takeda
• XMT-1536Mersana Therapeutics
• ZV05-ADC (5T4-MMAF ADC)Zova Biotherapeutics (Zova Bio); Concortis Biotherapeutics (a subsidiary of Sorrento Therapeutics)
• ZV203Concortis Biotherapeutics

X